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 Epstein-Barr Virus (EBV) is a nearly ubiquitous human herpesvirus which infects 
epithelial cells and B-lymphocytes. Additionally, long-term EBV latency has been 
associated with various forms of cancers including Burkitt’s lymphoma, nasopharyngeal 
carcinoma, and gastric carcinoma. Rapamycin, an mTORC1 inhibitor, has been 
demonstrated to suppress expression of the immediate-early gene BZLF1 and subsequent 
lytic replication in B-lymphocytes. Paradoxically, mTOR inhibition has also been 
reported to increase BZLF1 levels and lytic replication in epithelial cells. In order to 
identify possible mechanisms for this cell-specific response, a luciferase reporter assay 
using the BZLF1 promoter was performed in AGS-BX1 epithelial cells under mTOR 
inhibition. It was found that the removal of terminal YY1-binding domains resulted in the 
loss of rapamycin-sensitivity of BZLF1 transcription in AGS-BX1 cells. Furthermore, 
while YY1 was observed to localize to the nucleus of rapamycin-treated Raji B-
lymphocytes, little change was observed in YY1 localization in AGS-BX1 cells. These 
results, in conjunction with those of the luciferase assay, suggest YY1 may play an 
activating role of BZLF1 transcription in epithelial cells under mTOR inhibition while 
repressing viral transcription in B-lymphocytes. To test this hypothesis, both AGS-BX1 
cells and Raji cells were subject to YY1 knockdown using RNAi transfection and 
compared using Western Blotting. BZLF1 protein levels under mTOR inhibition in YY1-
knockdown AGS-BX1 cells were decreased, while significantly increased in the B-
 
 
lymphocytes under the same inhibition. These results suggest that YY1, as regulated by 
the mTOR pathway, may play an important role in the activation of the lytic cycle of 
EBV in epithelial cells, while simultaneously acting as a repressor to lytic replication in 
B-lymphocytes.
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 CHAPTER I 
INTRODUCTION 
 
1.1 Epstein-Barr Virus 
 Epstein-Barr Virus (EBV), also known as human herpesvirus 4, possesses a linear 
DNA genome, and is thought to currently infect over 90% of adult humans worldwide. 
Once transmitted to a new host, EBV is capable of entering and replicating within both 
epithelial cells and B-lymphocytes, potentially remaining unnoticed within the host for 
decades1. Though commonly associated with the nonlethal disease infectious 
mononucleosis, recent studies have associated long-term EBV infection with various 
malignancies such as nasopharyngeal carcinoma, endemic Burkitt’s lymphoma, and 
gastric carcinoma2. Though the exact mechanisms by which EBV promotes cell 
transformation is unknown, the high correlation between long-term EBV infection with 
these cancers suggests EBV has oncogenic properties. Similar to other members of the 
herpesviridae family, EBV has the ability to undergo either lytic replication or latency on 
a cell-dependent basis; undergoing solely lytic replication in epithelial cells and both lytic 
replication and latency within B-lymphocytes3. Lytic replication, either during the initial 
infection or induced from latency, is initiated by the expression of immediate-early genes 
BZLF1 (Zta) and BRLF1 (Rta). Zta and Rta act as transcription factors for both the viral 
and host genome; initiating the transcription of the second phase of lytic replication and 
altering host gene expression to maximize viral efficiency (Figure 1.1)
2 
 
 
Figure 1.1. Transcriptional Cascade of EBV Lytic Replication. After activation of 
immediate-early genes via various external and internal stimuli, early genes are 
expressed. Early genes begin the mass replication of the EBV genome within the host 
nucleus and activate late genes. Late gene products include virion capsid proteins and 
virion assembly chaperones, as well as latency promoting proteins to inhibit further 
activation of the immediate-early genes. 
 
 
Additionally, splicing of the BZLF1 and BRLF1 mRNA may result in the 
expression of a fusion protein called RAZ. RAZ, though retaining the DNA-binding 
domains and dimerization domains for Zta and Rta, lacks the transactivation domain. The 
expression of RAZ, therefore, inhibits Zta transactivation through the heterodimerization 
and sequestration of Zta; leading to the next phase of gene expression4. This second 
phase of viral gene expression, designated the early genes, initiate the replication of the 
viral genome and act as activators for the final wave of gene expression, late genes. Late 
genes encode proteins necessary for the assembly and release of newly formed, infectious 
viral particles. Within cells in which EBV is capable of entering latency, additional 
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proteins and noncoding RNAs are expressed following late gene expression. These 
proteins promote latency largely through the inhibition of Zta and Rta expression, as well 
as the epigenetic modification of the EBV genome and decrease of overall EBV gene 
expression. Latency proteins, such as EBNA1, may also alter host cell gene expression; 
leading to the downregulation of pro-apoptotic gene expression and subsequent cell 
immortalization5. In this state, EBV may remain latent for decades, only triggering lytic 
reactivation during the differentiation of B-cell in plasma cells6. 
 
1.2 mTOR and Rapamycin 
 The mammalian Target of Rapamycin (mTOR) is an evolutionarily conserved 
serine-threonine kinase that is ubiquitously expressed within mammalian cells7. Initiation 
of the mTOR pathway may be activated externally by receptor transduction cascades 
such as antigen receptors, Toll-like receptors, and cytokine receptors; or internally 
through shifts in ADP/ATP ratios or amino acids levels. Furthermore, downstream effects 
of mTOR activity include a wide range of functions including autophagy, cell growth, 
proliferation, immune responses, and cap-dependent translation (figure 1.2). 
Dysregulation of the mTOR pathway may lead to cellular abnormalities such as cancer 
and genetic defects8.  
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Figure 1.2. The Archetypal Activation of the mTOR Pathway. External activation of 
receptor tyrosine kinases by various growth factors initiate the AKT signaling pathway. 
AKT phosphorylation of the TSC1/2 complex releases Rheb, and allows for the 
interaction with and activation of mTORC1. Through regulation of the phosphorylation 
of downstream effectors, mTORC1 promotes a wide range of cellular changes including 
the initiation of cap-dependent translation. 
 
 
Directly upstream, mTOR is regulated through the release of the GTPase Rheb 
from the inhibitive TSC1/2 complex by phosphorylation though AKT. Rheb, no longer 
bound to the TSC1/2 complex, is then free to associate with and activate mTOR. 
Activated mTOR, though capable of targeting and phosphorylating a large number of 
substrates, is further regulated by the formation of specific complexes with additional 
proteins. mTOR complex 1 (mTORC1) is composed of the stable interaction of mTOR 
with Rheb, Raptor, Deptor, GL, and is the primary target of the mTOR inhibitor 
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rapamycin7. Rapamycin is a drug which was first isolated in 1975 from Streptomyces 
hygroscopicus, a streptomycete found in the soil of Easter island. While the drug was 
found to inhibit a variety of fungi, such as Candida albicans, Microsporum gypseum, and 
Trichophyton granulosum; the compound exhibited only a marginal inhibition of gram-
positive bacterial species and no inhibition of gram-negative species. Soon after, it was 
found that rapamycin also displayed anti-proliferative and immunosuppressive effects on 
other eukaryotic cells through the inhibition of the mTOR pathway. Rapamycin 
specifically inhibits mTORC1 by destabilizing interactions between mTOR and Raptor, 
thereby reducing mTOR’s ability to target and phosphorylate proteins9. The inhibition of 
mTOR has since been shown to suppress lytic activation of a variety of herpesviruses 
such as Kaposi’s sarcoma virus, cytomegalovirus, herpes simplex virus 1, and murine 
gammaherpesvirus. It was also recently discovered that mTOR inhibition alters EBV’s 
ability to enter lytic replication in a cell-specific manner. While rapamycin treatment 
leads to suppression of lytic replication of EBV in B-lymphocytes, lytic replication was 
significantly increased in epithelial cells. This increase of lytic replication was defined by 
increases in immediate-early gene protein levels, as well as increases in subsequent early 
gene protein levels10. 
 
1.3 Yin Yang 1 
 Yin yang 1 (YY1) is a ubiquitously expressed transcription factor known to play a 
crucial role in the transcription of cellular genes regulating proliferation, apoptosis, and 
differentiation, as well as several mitochondrial genes. Named for its ability to 
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simultaneously activate and repress the transcription of both cellar and viral genes, 
YY1’s activity is highly dependent upon post-translational modifications, localization, 
and protein interactions11. While YY1 protein interactions have been well-documented, 
little is known about the effects of the post-translational modifications. Post-translational 
modifications which are known to occur on YY1 include phosphorylation of 
serine/threonine and tyrosine residues, glycosylation, nitrosylation, sumosylation, 
acetylation, and methylation. Phosphorylation of YY1 is known to occur within two of 
the three zinc-finger DNA-binding domains, and is thought to alter DNA-binding 
efficiency12. YY1 is of particular interest for this study as YY1 has been demonstrated to 
interact with mTOR and Raptor of mTORC113, and is known to bind to and repress the 
promoters of EBV’s immediate-early genes, BZLF1 and BRLF1, in B-lymphocytes14, 23. 
Additionally, YY1 expression, localization, and DNA binding efficiency have been 
reported to vary substantially through cell cycling15, 16.  
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Figure 1.3. Possible Mechanisms by which Rapamycin-induced mTOR Inhibition 
Affects Changes in Protein Expression. Since the mTOR pathway may lead to changes 
in both transcription factor activity and cellular cap-dependent translation, it is unknown 
whether cell-specific EBV activation is the result of altered transcription or translation.  
 
 
1.4 Project Overview 
 The mTOR pathway is a ubiquitous and vital pathway for sensing and regulating 
cellular processes including metabolism, growth, transcription, and cap-dependent 
translation7. While activation of Epstein-Barr Virus lytic replication is expectedly 
repressed by mTOR inhibition in B-lymphocytes, it is paradoxically increased in 
epithelial cells10. As a downstream target of mTOR activity, the transcription factor Yin 
yang 1 is a common regulator of cellular and viral gene expression and is known to bind 
to the promoter elements of both EBV immediate-early genes14. The goal of this study 
was to determine if the cell-specific changes of EBV lytic activation in response to 
mTOR inhibition is specifically mediated through the activity of YY1 (figure 1.3). 
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1.5 Specific Aims 
1. Analyze the relative BZLF1 levels under chemical mTOR inhibition within 
epithelial cells and B-lymphocytes at various time points post-induction of 
EBV lytic replication. 
2. Use luciferase reporter constructs to determine the relative contribution of 
upstream segments of the BZLF1 promoter to gene expression under chemical 
mTOR inhibition. 
3. Elucidate the degree and direction of YY1 localization changes under mTOR 
inhibition in epithelial cells and B-lymphocytes. 
4. Determine the effects of YY1 knockdown in epithelial cells and B-
lymphocytes under chemical mTOR inhibition.
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CHAPTER II 
METHODS 
 
 
2.1 Reagents 
 Raji B-lymphocytes and AGS-BX1 cells were obtained from ATCC and gifted 
from L. Hutt-Flechter respectively. Cells were grown in Ham’s F12 supplemented with 
10 fetal bovine serum and treated with penicillin, streptomycin, fungicide and 500ug/mL 
G418. Lytic replication was induced using 20ng/mL TPA, 3mM sodium butyrate for B-
lymphocytes; and 5ng/mL TPA, 0.75mM sodium butyrate for epithelial cells (both from 
Sigma-Aldrich). Rapamycin in DMSO was obtained from Sigma-Aldrich. pGL3-Basic 
and pGL4.75 plasmids18 were purchased from Promega, with specific primers obtained 
from Eurofins. Plasmid isolation and purification was performed using a Qiagen Maxi 
column and suspended in TE buffer (10nM Tris-HCl pH 8.0, 1mM EDTA). YY1 
knockdown was performed using a Qiagen YY1 RNA probe kit, and controlled against 
the Qiagen All-Stars scrambled RNA reagent. Chemical transfection was achieved using 
Lipofectamine 200019 for epithelial cells, and additional 2 second electroporation at 
250V, 950mA for B-lymphocytes. Luciferase reagents were purchased from Promega and 
mixed prior to each luciferase assay20. Whole protein extraction was performed by 
suspending cells in lysis buffer (0.25M NaCl, 0.1% NP40, 50nM HEPES, 5nM EDTA), 
subjecting cells to two freeze/thaw cycles, centrifugation, and collection of the resulting 
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supernatant. Cytosolic protein extraction was performed by treating whole cells with CE 
buffer + NP-40 (10mM Hepes pH 7.6, 60mM KCl, 1mM EDTA, 1mM DTT, 0.7% NP-
40). After harvesting cytosolic proteins, nuclei were washed using CE buffer two times 
before being suspended in lysis buffer and undergoing the previously mentioned whole 
protein extraction protocol. Separated proteins were transferred to Immobulin (Millipore) 
membranes and blocked using a blocking buffer (0.25% dried milk powder with 1% 
Tween-20 and 1xPBS). Anti-BZLF1, anti-Tubulin, anti-YY1, and anti-TBP antibodies 
(Santa Cruz or Cell signaling) were used to probe Western blots using a dilution of 1:500 
in 0.25% milk blocking solution. Secondary antibodies (goat anti-rabbit or rabbit anti-
mouse; from Jackson Immunoresearch) were diluted at 1:5000 in 0.25% milk blocking 
buffer and used for visualization with Advansta reagents on a Li-Cor blot developer. 
 
2.2 Cell Culture 
 As a model for epithelial cells throughout these experiments, a AGS-BX1 gastric 
carcinoma cell line was used. Though EBV is typically unable to undergo latency in 
epithelial cells, AGS-BX1 cells contain the viral genome containing a G418 resistance 
gene which is only expressed while the viral genes are transcriptionally silenced. By 
using AGS-BX1 cells, the presence of the EBV genome was not only ensured through 
G418 selection, but lytic replication could also be inhibited. Additionally, EBV has 
already demonstrated enhanced activation in AGS-BX1 under mTOR inhibition. The 
AGS-BX1 cell line was grown at 37oc in 20mL of supplemented Ham’s F12 media 
(Ham’s F12, 10% fetal bovine serum, fungicide, streptomycin, and penicillin) in a 
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150cm2 culture flask until confluent. At confluency, 2mL of the non-enzymatic cell 
dissociation solution Cellstripper was used to collect AGS-BX1 cells, after which cells 
were washed in 1x sterile phosphate buffered saline (PBS) to remove residual 
dissociation solution, and redistributed onto 60mm plates with 5mL of supplemented 
Ham’s F12 and G418. Prior to rapamycin treatment, plates containing AGS-BX1 cells 
were washed in sterile 1x PBS to remove residual G418, and re-aliquoted 5mL of 
supplemented Ham’s F12. Viral induction was achieved by the removal of G418 and 
subsequent treatment with 5ng/mL TPA, 0.75mM sodium butyrate. 
 Raji Burkitt’s lymphoma cells were selected as the model cell line for B-
lymphocytes due to Raji cells possessing a latent EBV genome and were previously 
identified to display reduced lytic activation under mTOR inhibition. Raji cells were 
grown at 37oc in a 150cm2 culture flask with supplemented RPMI media (RPMI, 10% 
fetal bovine serum, fungicide, streptomycin, and penicillin) until confluent. Unlike AGS-
BX1 cells, Raji cells are neither adherent nor require G418 selection to maintain latency 
of the EBV genome. As such, Raji cells were collected and washed in 1x sterile PBS 
without the use of a dissociation solution, and then aliquoted into 25cm2 culture flasks 
containing only 5mL of the supplemented RPMI. In order to induce lytic replication, cells 
were treated with 20ng/mL TPA, 3mM sodium butyrate. 
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2.3 Western Blot for BZLF1, YY1, and Tubulin 
 Protein extraction of harvested AGS-BX1 and Raji cells was performed by 
washing cells in sterile 1mL of 1x PBS, followed by suspension in 30uL of lysis buffer 
(0.25M NaCl, 0.1% NP40, 50nM HEPES, 5nM EDTA) with protease/phosphatase 
inhibitors. This suspension then underwent two freeze/thaw cycles at -80oc and 37oc 
respectively, and spun down at 12000rpms for 10 minutes prior to harvesting the 
resulting supernatant. Protein extracts was then quantified using an Eppendorf Bio 
Photometer. For each sample, the appropriate volume of extract to contain 20ug of 
protein was then aliquoted into an equal volume of protein dye and boiled at 100oc for 2 
minutes. Prepared protein extracts were separated using 10% SDS-PAGE at 200V and 
transferred to Immobulin PVDF at 100mA overnight. The resulting western blots were 
blocked in a 0.25% milk solution (0.5g powdered milk, 0.1% Tween 20, 1x PBA) using 
the SNAP I.D. 2.0 vacuum system. Immunostaining was then performed by incubating 
blocked blots with Santa Cruz (BZLF1, Tubulin, YY1) or Cell signaling (TBP) primary 
antibodies in a 1:500 dilutions of 0.25% milk solution. Incubated blots were then washed 
three times with Western wash (0.1% Tween 20, 1x PBS) and incubated with secondary 
antibodies (Jackson Immunoresearch rabbit anti-mouse or goat anti-rabbit) diluted at 
1:5000 for 10 minutes. After three washes, the probed blots were placed in Li-Cor 
WesternSure ECL substrate, developed using a Li-Cor blot developer at high exposure, 
and stored at 0oc. The detected protein bands were quantified using Image Studio Digital 
software and recorded for data analysis.  
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2.4 Luciferase Reporter Plasmid Construction 
 To construct the luciferase reporter plasmids, a pGL-3 Basic expression vector 
containing a luciferase gene, an ampicillin resistance gene, and cloning site was obtained 
from Promega and amplified in DH5- E. coli in 200mL of ampicillin containing Lim 
broth (LB). The amplified plasmid was purified using a Qiagen Plasmid Maxi extraction 
column and analyzed for purity using a NanoDrop ND-1000 Spectrophotometer. 
Promoter inserts were generated by PCR of the BZLF1 promoter using forward and 
reverse primers containing Bgl11 and Hind111 restriction endonuclease sites 
respectively. Five individual forward primers and a single reverse primer corresponding 
to the transcriptional start site were used to generate 509, 409, 359, 309, and 259bp 
lengths of the BZLF1 promoter (figure 2.1). The template EBV genome was extracted by 
using a modified Hirt procedure for extrachromosomal DNA purification21 from 
untreated Raji B-lymphocytes.  
 
 
Figure 2.1. BZLF1 Promoter and Luciferase Reporter Construct Inserts. Each insert 
designation corresponds to the length of the insert starting at the transcriptional start site 
and moving in the upstream direction. 
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Following amplification of these promoter inserts, both the pGL3-Basic plasmids 
and inserts were digested with Bgl11 and Hind111 restriction endonucleases for three 
hours at 37oc and separated on a 0.8% agarose gel. The DNA bands corresponding to the 
digested plasmid and insert were purified from the agarose gel, mixed at a 1:2 ratio in the 
presence of T4 DNA ligase, and incubated at room temperature overnight. The 
constructed plasmids then transformed into chemically-competent DH5- E. coli, which 
were plated onto ampicillin-containing LB agarose plates and incubated overnight at 
37oc. Individual colonies were isolated and grown on separate ampicillin LB agar plates 
and confirmed as containing the specific reporter plasmid through PCR. Colonies which 
tested positive for the desired promoter length were then amplified in 200mL of 
ampicillin LB broth, harvested, and purified for the reporter plasmid in TE buffer. Each 
reporter plasmid purification was then analyzed for optical density and labelled according 
to its promoter length. Additionally, each purified constructed reporter plasmid sample 
was sent for DNA sequencing to Eurofins (figure 2.2). The resulting DNA sequences 
were analyzed using BLAST nucleotide to ensure the presence of the intended viral 
promoter and lack of procedural mutations in the promoter sequences. 
15 
 
 
 
Figure 2.2. DNA Sequence of BZLF1 Promoter Inserts. Each insert name corresponds 
to the each of the promoter insert, with ZP(-509) representing the full-length BZLF1 
promoter. BLAST nucleotide analysis of the sequenced promoter inserts had a 100% 
match to known EBV BZLF1 sequences. 
 
2.5 Transfection of Nucleic Acids 
For transfection of nucleic acids into epithelial cells, 60mm plates of AGS-BX1 
were grown to confluency in supplemented Ham’s F12 media under G418 suppression. 
Immediately prior to transfection, cells were washed in sterile 1x PBS and placed in 5mL 
of Ham’s F12 media. Transfection media for the luciferase reporter assay was prepared 
using 3ug of BZLF1 promoter pGL-3 plasmid and 3ug of the constitutively active renilla 
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reporter plasmid pGL-4.75 in 300uL of Ham’s F12 media. The transfection media for the 
YY1 knockdown, alternatively, used either 3uL of each of the four Qiagen YY1 siRNAs 
(12uL in total) or 12uL of Qiagen All-Star scrambled RNA suspended in 300uL of Ham’s 
F12 media. Concurrently, 6uL of Lipofectamine 2000 transfection reagent was added to 
aliquots of 300uL Ham’s F12 for each nucleic acid suspension. The nucleic acid and 
Lipofectamine suspensions were then mixed to a volume of 600uL and incubated at room 
temperature for 20 minutes. Each 60mm plate of AGS-BX1 cell was then treated with 
100uL of the transfection media for 24-hours, after which media was washed off using 
sterile 1x PBS and replaced with supplemented Ham’s F12 media. AGS-BX1 cells 
transfected with luciferase reporter plasmids were treated immediately following removal 
of transfection media while YY1 knockdown AGS-BX1 cells were treated with G418 and 
incubated an additional 4 days prior to the removal of G418 media, washing with sterile 
1x PBS, addition of supplemented Ham’s F12 media, and subsequent experimentation. 
Raji B-lymphocytes were transfected using a novel combination of Lipofectamine 
2000 chemical transfection and electroporation which produced higher transfection rates 
than either method individually. The transfection media used for electroporation of the 
four Qiagen YY1 siRNAs in Raji cells was prepared with the same protocol used for 
AGS-BX1 transfection media but using RPMI in lieu of Ham’s F12. At confluency, 6mL 
of Raji cells in enriched RPMI were collected, washed in sterile 1x PBS, and suspended 
in 3mL of cold RPMI media. 500uL of the Raji suspension was then pipetted into 
electroporation cuvettes along with 100uL of the transfection media, and left on ice for 
10 minutes prior to electroporation. Each sample was then electroporated at 950uF, 250V 
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for 2 seconds and incubated on ice for an additional 10 minutes. Electroporated Raji cells 
were then added to individual 25cm2 culture flasks containing 5mL of supplemented 
RPMI, and incubated at 37oc for 4 days prior to rapamycin treatment. The Raji 
electroporation protocol was then confirmed using pGL4.75 renilla luciferase as a marker 
for transfection. All luciferase reporter assays were performed on a Biotek Synergy 2 
plate reader in accordance with the luciferase reporter assay protocol. 
 
2.6 Luciferase Reporter Assay 
 AGS-BX1 cells transfected with luciferase reporter plasmids were treated with 
0nM, 1nM, 5nM, or 10nM rapamycin immediately following removal of transfection 
media. After 24 hours of rapamycin treatment, EBV lytic replication was induced using 
5ng/mL TPA, 0.75mM sodium butyrate for an additional 24 hours before cells were 
harvested. Cells were scraped from their individual plates, washed in sterile 1xPBS, 
suspended in 75uL of 1xPBS on an optically clear 96-well plate, and treated with the 
Promega DualGlo Luciferase Assay kit reagents. After a 10-minute incubation period at 
room temperature, expression of the BZLF1-controlled luciferase reporter plasmid and 
constitutively-active renilla luciferase plasmid were separately quantified using a BioTek 
Synergy 2 spectrophotometric plate reader. Luciferase expression of the BZLF1 promoter 
constructs and renilla luciferase plasmids were expressed as relative light units (RLUs) 
and recorded for data analysis. Five biological replicates and two technical replicates 
were collected and analyzed for each of the five constructed plasmids. 
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2.7 YY1 Localization 
 To determine if rapamycin treatment and/or EBV induction resulted in shifts in 
YY1 localization, nuclear and cytosolic extracts were collected for individual analysis. 
AGS-BX1 and Raji cells were grown to confluency in supplemented Ham’s F12 and 
RPMI media respectively, treated with 0nM, 1nM, 5nM, and 10nM rapamycin for 24 
hours, and induced with TPA/NaBut for an additional 24 hours. To collect the cytosolic 
extract, cells were harvested and suspended in CE buffer (10mM HEPES, 60mM KCl, 
1mM EDTA, 1mM DTT) + 0.7% NP-40 with protease/phosphatase inhibitors, and 
incubated on ice for 5 minutes. The resulting mixtures were spun down at 8000rpm for 4 
minutes prior to the collection of the supernatant, labelled cytosolic extract. The resulting 
pellet was then washed twice in CE buffer and suspended in 100uL of CE + 0.7% NP-40 
with protease/phosphatase inhibitors. The suspension was subject to two freeze/thaw 
cycles and centrifuged at 10,000rpm for 10 minutes. The resulting supernatant for each 
sample was collected and labeled as the nuclear extract. Both the cytosolic and nuclear 
extracts were analyzed for optical density using the NanoDrop ND-1000 
Spectrophotometer and separated using 10% SDS-PAGE using 20ug of protein per well. 
The separated proteins were transferred to Immobulin PVDF membranes using Western 
Blot, and probed for YY1. Standardization of YY1 quantifications were performed using 
either tubulin or TATA-binding protein (TBP) for the cytosolic and nuclear extracts 
respectively. Normalized YY1 quantifications were then standardized to the untreated, 
uninduced sample, and expressed as a ratio of the normalized nuclear extract to the 
normalized cytosolic extract.  
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2.8 YY1 Knockdown 
 In order to measure the potential role of YY1 in BZLF1 expression under mTOR 
inhibition, YY1 knockdown studies were performed in AGS-BX1 and Raji cells. Both 
AGS-BX1 and Raji cells were first transfected with four Qiagen YY1 siRNAs using their 
respective transfection methods. Initial experimentation of YY1 knockdown determined 
that the greatest level of YY1 depression occurred on day six post-transfection (Figure 
3.13). As such, both transfected cell lines were treated with 0nM, 1nM, 5nM, or 10nM 
rapamycin on day four, induced with TPA/NaBut on day five, and harvested on day six. 
Cells were washed in sterile 1x PBS and subject to whole cell protein extraction using 
ELB lysis buffer with protease and phosphatase inhibitors. 20ug of each protein extract 
was then separated using 10% SDS-PAGE and compared with Western Blotting. The 
resulting blots were immunostained for BZLF1 and tubulin, and developed using the Li-
Cor Western blot developer. BZLF1 band quantifications were normalized using tubulin 
band quantifications, and held relative to the normalized untreated induced value.  
 
2.9 Data Analysis 
For Western blot immunostaining, BZLF1 and YY1 quantification values were 
normalized using either tubulin or TBP as a loading control, with normalized values held 
relative to the untreated, induced sample. YY1 localization was further expressed as a 
ratio of the normalized, relative values of the nuclear extract to the cytosolic extract. 
Standard error was calculated by dividing the standard deviation of all normalized, 
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relative quantifications by the square of the number of samples. Significance was tested 
using a heteroscedastic student two-tailed T-test, with p<0.05 considered significant. 
Results of the luciferase reporter assay were analyzed by dividing the RLUs of the 
BZLF1 promoter construct by those of the renilla luciferase. This allowed for the 
variation in sample transfection efficiency, as well global, non-specific changes of 
transcription, to be controlled. These normalized RLU values were then held relative to 
the untreated, induced condition within each replicate. Standard error was calculated by 
dividing the standard deviation of all normalized, relative values by the square of the 
number of samples. Significance was tested using a heteroscedastic student two-tailed T-
test, with p<0.05 considered significant.
21 
 
CHAPTER III 
RESULTS 
 
 
3.1 Changes in Expression Patterns of BZLF1 in AGS-BX1 and Raji Cells Under 
mTOR Inhibition 
As predicted from the literature, levels of BZLF1 in untreated Raji B-lymphocytes 
increased from undetectable levels at the 0 hour, to a maximum at 16 hours post-
induction before decreasing3. While protein levels appeared to increase again at 24 hours 
post-induction, these levels do not reach those seen at 16 hours. BZLF1 levels in the 5nM 
rapamycin-treated Raji cells, however, remained greatly reduced relative to the untreated 
group at every hour post-induction (figure 3.1). Additionally, instead of forming two 
expressive peaks at 16 hours and 24 hours post-induction, BZLF1 levels in rapamycin-
treated Raji cells formed only a single, long peak at 20 hours post-induction.  
A similar pattern of BZLF1 expression was seen in the untreated AGS-BX1 cells 
as found in the Raji cells. Protein levels of BZLF1 increased after induction to a 
maximum at 16 hours post-induction before decreasing between 18-20 hours post 
induction (figure 3.2). At 24 hours post-induction, however, BZLF1 levels increased 
again to levels similarly expressed at 16 hours. BZLF1 levels in rapamycin-treated AGS-
BX1 cells displayed a single peak of expression at 18 hours post-induction, representing a 
20% increase in BZLF1 protein relative to the untreated cells.
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Figure 3.1. Relative Expression of BZL1 in Raji B-lymphocytes Over Time. While 
BZLF1 in untreated Raji cells formed peaks at 16 and 24 hours post-induction, BZLF1 
levels in cells treated with 5nM rapamycin did not substantially increase in expression 
relative to the untreated group. Data set represents two biological replicates, each with 
two technical replicates. 
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Figure 3.2. Relative Expression of BZLF1 in AGS-BX1 Epithelial Cells Over Time. 
While the rate of increase in BZLF1 expression appeared consistent between the treated 
and untreated groups, BZFL1 levels continued to increase in the 5nm rapamycin treated 
group; forming an expressive peak at 18 hours post-induction. Data set represents two 
biological replicates, each with two technical replicates. 
 
3.2 Relative Contribution of YY1 Binding Domains on BZLF1 Expression in AGS-
BX1 Cells 
In AGS-BX1 cells, each luciferase reporter plasmid was assayed to look for 
changes in rapamycin sensitivity, as well as general changes in expression relative to the 
untreated, uninduced control (Figure 3.3). ZP(-509), which contained the entirety of the 
known BZLF1 promoter, displayed an expression pattern similar to that of the BZLF1 
protein levels: luciferase expression positively correlated with increases in rapamycin 
treatment, and decreased spontaneous activation of luciferase expression with rapamycin 
treatment (Figure 3.4). Unlike the BZLF1 protein levels, however, luciferase levels in the 
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rapamycin-treated, induced cells were reduced relative to the untreated, induced cells. 
The deletion of the first 100bp of the BZLF1 promoter appears to result in both 
rapamycin insensitivity as no significant differences (p > 0.75) were noted between the 
untreated and treated induced samples (Figure 3.5). Additionally, loss of rapamycin-
associated suppression of spontaneous transcription was also seen in the ZP(-409) 
reporter plasmid. This loss of the rapamycin-associated spontaneous expression, and even 
the partial increase in spontaneous expression, was further seen in the ZP(-359), ZP(309), 
and ZP(-259) plasmids. Positively correlated rapamycin sensitivity was seen in ZP(-359) 
plasmids, and at a greater degree of enhancement than in ZP(-509) (Figure 3.6). This 
enhancement, however, was lost in both ZP(-309) and ZP(-259) plasmids with the 
deletion of the final YY1 domain (Figure 3.7 and Figure 3.8). In addition, luciferase 
expression of ZP(-259) in all rapamycin treated, induced cells were reduced relative to 
the untreated, induced standard. In comparison to the full length ZP(-509) promoter, only 
ZP(-409) reporter plasmid expressed reduced relative expression of luciferase activity 
(Figure 3.9) as determined by standardizing to the untreated, uninduced control. The 
other three plasmids increasingly expressed elevated luciferase expression which 
inversely correlated with promoter length.  
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Figure 3.3. BZLF1 Promoter Luciferase Reporter Assay. Results are standardized to 
the untreated, uninduced sample in each plasmid. While ZP(-409) expressed lower levels 
of luciferase expression than ZP(-509), the other three plasmids consistantly expressed 
elevated levels of luciferase compared to the full-length BZLF1 promoter. Data sets 
represent five biological replicates with two technical replicates. 
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Figure 3.4. Luciferase Reporter Assay Results of the ZP(-509) Plasmid. These results 
mimic with the observed patterns in BZLF1 protein expression such as positive 
correlation between expression and rapamycin concentration, and rapamycin suppression 
of leaky activation in the treated, uninduced sample. Data set represent five biological 
replicates with two technical replicates. 
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Figure 3.5. Luciferase Reporter Assay Results of the ZP(-409) Plasmid. Loss of 
rapamycin sensitivity in both induced and uninduced groups were seen. Data set 
represent five biological replicates with two technical replicates. 
 
 
 
 
Figure 3.6. Luciferase Reporter Assay Results of the ZP(-359) Plasmid. Though 
luciferase expression was positively correlated with increasing rapamycin concentrations 
in induced samples, insensitivity to rapamycin in the 5nM, uninduced sample was 
observed. Data set represent five biological replicates with two technical replicates. 
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Figure 3.7. Luciferase Reporter Assay Results of the ZP(-309) Plasmid. Rapamycin 
insensitivity was observed the 5nM, uninduced sample. Additionally, an inverse 
correlation between luciferase expression and rapamycin concentration appears in the 
treated, induced groups. Data set represent five biological replicates with two technical 
replicates. 
 
 
 
 
 
 
 
 
29 
 
 
 
Figure 3.8. Luciferase Reporter Assay Results of the ZP(-259) Plasmid. Rapamycin 
sensitivity appears to be lost in both induced and uninduced cells. Additionally, luciferase 
levels are reduced relative to the untreated, induced standard. Data set represent five 
biological replicates with two technical replicates. 
 
 
 
 
 
 
 
 
30 
 
 
 
Figure 3.9. BZLF1 Promoter Reporter Assay of Untreated and Treated Uninduced 
AGS-BX1 Cells. After the deletion of the -509bp to -410bp section of the promoter, 
rapamycin suppression of leaky transcription is reduced. Further deletions of the 
promoter result in increases in leaky transcription. Data set represent five biological 
replicates with two technical replicates. 
 
 
3.3 Shifts in YY1 Localization Due to mTOR Inhibition and Viral Induction in 
AGS-BX1 and Raji Cells 
After quantification of YY1 protein bands in both the nuclear extract (NE) and the 
cytosolic extract (CE), the ratio NE/CE was used to generalize YY1 localization in each 
condition (Figure 3.10). NE/CE values were then standardized to the untreated, 
uninduced sample. Samples in which the NE/CE ratio was greater than 1 were considered 
to have YY1 localization to the nucleus; while samples with a NE/CE ratio less than one 
were considered to have YY1 localization to the cytosol.  The Raji B-lymphocytes 
consistently demonstrated YY1 localization to the nucleus, with the highest nuclear 
localization occurring the 5nM treated, induced sample (Figure 3.11). Interestingly, 
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while YY1 localization appears to compound with viral induction and rapamycin 
treatment in the 1nM and 5nM groups, the 10nM treated, induced group displayed a YY1 
localization ratio similar to the 5nM treated, uninduced group. AGS-BX1 epithelial cells 
demonstrated only a slight localization to the cytosol which did not correlate with 
increasing concentrations of rapamycin or induction state (Figure 3.12).  
 
 
Figure 3.10. Cytosolic Localization Versus Nuclear Localization of YY1 in AGS-
BX1 Epithelial Cells and Raji B-lymphocytes. Cytosolic extract (CE) YY1 
quantifications were normalized to tubulin and nuclear extract (NE) YY1 quantifications 
were normalized to Tata-Binding Protein. Localization was determined by taking a ratio 
of normalized NE to CE YY1 quantifications. 
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Figure 3.11. YY1 Localization in Raji B-lymphocytes. NE/CE ratios greater than 1 
correlate to nuclear localization of YY1, while values less than 1 correlate to cytosolic 
localization of YY1. Relative to the untreated, uninduced condition, YY1 appeared to 
shift into the nucleus in every condition. This may be the result of combinatorial effects 
of mTOR inhibition and initiation of EBV latency.  Data set represents three biological 
replicates with two technical replicates each. 
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Figure 3.12. YY1 Localization in AGS-BX1 Epithelial Cells. NE/CE ratios greater 
than 1 correlate to nuclear localization of YY1, while values less than 1 correlate to 
cytosolic localization of YY1. YY1 did not appear to undergo significant localization 
shifts, with the exception of the 10nM rapamycin treated, induced sample, in which YY1 
is localized to the cyosol. Data set represents three biological replicates with two 
technical replicates each. 
 
 
3.4 RNAi Mediated Knockdown of YY1 in AGS-BX1 and Raji Cells Alters 
Expression of BZLF1 
Though BZLF1 levels in the YY1 knockdown treated, induced AGS-BX1 
samples were still elevated relative to the untreated control, the degree of increase in 
protein expression was substantially reduced compared to samples transfected with only 
scrambled RNA (Figure 3.15 and Figure 3.17). This effect was most pronounced at the 
1nM and 10nM rapamycin treated, induced cells and, overall, demonstrated a loss in 
rapamycin-sensitivty. In contrast, 1nM and 5nM treated, induced YY1 knockdown Raji 
cells exhibited an increase in BZLF1 levels (Figure 3.14 and Figure 3.16). This increase 
was both in comparison to the scrambled RNA transfected control and the YY1 
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knockdown untreated, induced control. Despite this, BZLF1 levels still displayed a 
negative relationship with increasing concentrations of rapamycin. 
Overall changes in BZLF1 expression was also analyzed for AGS-BX1 cells by 
standardizing normalized BZLF1 levels to the untreated, uninduced control. In the YY1 
knockdown AGS-BX1 cells, BZLF1 protein levels increased relative to those in the 
scrambled control the 5nM, uninduced and 0nM, induced samples (Figure 3.18). 
Substantial changes were not detected in BZLF1 levels of the 1nM and 5nM treated, 
induced groups, though a large decrease in relative protein levels was found in the 10nM, 
induced group. 
 
 
 
Figure 3.13. YY1 Knockdown in AGS-BX1 Epithelial Cells and Raji B-lymphocytes. 
The average YY1 knockdown on day six in AGS-BX1 cells after normalization with 
tubulin was 39%, while the average YY1 knockdown on day six in Raji cells after 
normalization with tubulin was 20%. YY1 knockdown and scrambled RNA control were 
repeated twice in each cell line with two technical replicates per repetition.  
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Figure 3.14. BZLF1 Expression of Negative Control and YY1 Knockdown AGS-
BX1 Epithelial Cells. The negative control (a) was transfected with scrambled RNA and 
subject to the same treatment protocol as the YY1 knockdown group (b). Lane 1 – 0nM 
rapamycin, uninduced, lane 2 - 5nM rapamycin, uninduced, lane 3 – 0nM rapamycin, 
induced, lane 4 – 1nM rapamycin, induced, lane 5 – 5nM rapamycin, induced, lane 6 – 
10nM rapamycin, induced. 
 
 
 
 
Figure 3.15. BZLF1 Expression of Negative Control and YY1 Knockdown in Raji B-
lymphocytes. The negative control (a) was transfected with scrambled RNA and subject 
to the same treatment protocol as the YY1 knockdown group (b). Lane 1 – 0nM 
rapamycin, uninduced, lane 2 - 5nM rapamycin, uninduced, lane 3 – 0nM rapamycin, 
induced, lane 4 – 1nM rapamycin, induced, lane 5 – 5nM rapamycin, induced, lane 6 – 
10nM rapamycin, induced. 
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Figure 3.16. Comparison of Relative Expression of BZLF1 Between YY1 
Knockdown AGS-BX1 Epithelial Cells and the Negative Control. Decreases in 
BZLF1 were seen in the rapamycin treated, induced groups of YY1 knockdown cells 
compared to the scrambled RNA negative control. Data set represents four biological 
replicates with two technical replicates each. 
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Figure 3.17. Comparison of Relative Expression of BZLF1 Between YY1 
Knockdown Raji B-lymphocytes and the Negative Control. BZLF1 levels were 
significantly increased in rapamycin treated, induced YY1 knockdown Raji cells 
compared to both the scrambled negative control and the untreated, induced standard at 
1nM. Protein levels were also increased at 5nM in YY1 knockdown Raji cells, but are 
depressed at 10nM rapamycin treatment. Data set represents four biological replicates 
with two technical replicates each. 
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Figure 3.18. Overall Expression of BZLF1 in YY1 Knockdown and Scrambled RNA 
Transfected AGS-BX1 Epithelial Cells. Though overall BZLF1 levels are not 
substantially altered in the treated, induced groups, protein levels were elevated in both 
the 5nM, uninduced and 0nM, induced YY1 knockdown cells. Also, BZLF1 in the 10nM, 
induced YY1 knockdown cells were decreased compared to the scrambled control. Data 
set represents four biological replicates with two technical replicates each. 
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CHAPTER IV 
DISCUSSION 
 
 
4.1 Changes in Expression Patterns of BZLF1 in AGS-BX1 and Raji Cells Under 
mTOR Inhibition 
 The highest peak of expression of BZLF1 was at 16 hours post-induction in the 
untreated Raji B-lymphocytes after which BZLF1 levels decreased though still remained 
elevated compared to the 5nM rapamycin treated cells. At 24 hour post-induction, BZLF1 
levels began to increase again, though not to the levels seen at the 16 hour point. This 
suggests that there may be multiple waves of initiation of immediate-early gene 
activation, culminating with elevated levels of BZLF1 at 16 hours and at 24 hours. 
Though BZLF1 levels did increase in the 5nM rapamycin treated Raji cells, protein levels 
peaked at the 20 hours post-induction; producing only 20% of untreated 24 hour levels. 
The immediate disparity between protein levels of the treated and untreated groups 
suggest that rapamycin suppression of BZLF1 occurs during the initial activation of 
BZLF1, rather than the premature initiation of latency. By inhibiting the initial expression 
of BZLF1, insufficient levels of the immediate-early gene are transcribed to produce 
normal lytic replication. Additionally, since the pattern of expression in the treated Raji 
cells only a single long peak compared to the double peak seen in the untreated cells, it 
supports the hypothesis that mTOR inhibition is affecting BZLF1 expression at a 
transcriptional level rather than simple decreasing translation efficiency.  
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BZLF1 levels in untreated epithelial cells also demonstrated a maximum peak at 
16 hours post-induction. Unlike the expression pattern seen in the untreated B-
lymphocytes, BZLF1 levels further increased at the secondary peak at 24 hour post-
induction time point. This suggests that, while multiple rounds of expression may occur 
in untreated, induced AGS-BX1 and Raji cells, the secondary waves are decreased in Raji 
cells and increased in AGS-BX1 cells. This is supported by the observation that EBV is 
able to undergo latency in B-lymphocytes but not in epithelial cells. It may be that 
latency associated products, such as EBNA1, are produced following late-gene 
expression, thereby decreasing secondary waves of lytic expression in B-lymphocytes. 
EBV does not produce EBNA1 in epithelial cells, so lytic replication is allowed to 
continue in an increasing cycle of expression.  
Epithelial cells treated with 5nM rapamycin support the hypothesis that mTOR 
inhibition increases BZLF1 expression in EBV induced epithelial cells by prolonging 
BZLF1 expression. While the pattern of BZLF1 expression between the treated and 
untreated groups was initial similar, BZLF1 expression continued to increase after 16 
hours; forming an initial peak at 18 hours post-induction. While BZLF1 levels then fell, 
mirroring the expression pattern seen in untreated cells, the secondary peak of BZLF1 at 
24 hours remained elevated compared to the untreated cells. Since the early expression 
patterns between the treated and untreated groups were similar, and differences only 
arose later, initial activation of BZLF1 appeared unaffected in the treated epithelial cells. 
This suggests that BZLF1 expression in epithelial cells, under mTOR inhibition, is 
subject to prolonged activation. Additionally, since the expressive patterns between the 
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two groups were initial similar, this evidence again supports the theory that rapamycin-
associated activation of lytic replication in epithelial cells is a result of transcriptional 
upregulation. 
 
4.2 Relative Contribution of YY1 Binding Domains on BZLF1 Expression in AGS-
BX1 Cells 
 The results of the full-length BZLF1 promoter containing plasmid ZP(-509) 
supports the hypothesis that mTOR inhibition mechanistically affects BZLF1 
transcriptional activation in epithelial cells.  While luciferase activity was partially 
repressed by rapamycin treatment relative to the 0nM, induced control, increasing 
concentrations of rapamycin positively correlated with increases in luciferase activity. 
The impact of upstream deletions on luciferase activity was compared against the ZP(-
509) plasmid for the other reporter constructs. ZP(-409), which was the result of a YY1 
domain and E2-2 domain deletion, saw immediate loss of rapamycin sensitivity in both 
induced and uninduced samples, and an overall decrease in expression relative to the 
untreated, uninduced control. This suggests that elements in the -509 to -409bp region of 
the BZLF1 promoter are activating, and responsive to mTOR inhibition. The overall 
repressive result of this 100bp deletion is likely due to the loss of the terminal E2-2 
domain, as earlier work has demonstrated that site-directed mutagenesis of this region 
shows a similar repression22. In order to determine if the loss of rapamycin sensitivity 
was due to E2-2 or YY1 deletions, ZP(-359), ZP(-309), and ZP(-259) were also 
compared. The ZP(-359) plasmid displays both a dramatic increase in expression relative 
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to the untreated, uninduced control, and the reemergence of rapamycin-sensitivity. Since 
two E2-2 and a single YY1 domain were deleted to produce the ZP(-359) plasmid, it was 
still uncertain if these changes were attributable to YY1 or E2-2 deletions. In ZP(-309), 
which maintains a E2-2 domain bute deletes the final YY1 domain, rapamycin sensitivity 
is lost and no change in overall protein expression relative to the untreated, uninduced 
was observed. The final 50bp deletion in ZP(-259) removed the final E2-2 domain but 
did not alter the rapamycin sensitivity. Interestingly, however, overall luciferase 
expression was increased in the induced cells (Figure 3.3). These results suggest that the 
YY1 domains are principally involved in the rapamycin sensitivity of BZLF1 
transcription in epithelial cells. While E2-2 domains may play a role in the overall 
responsiveness of the BZLF1 promoter to lytic activation, these increases are rapamycin 
insensitive. Furthermore, the upstream E2-2 domain appears to be important in 
rapamycin-associated suppression of spontaneous transcription, as luciferase activity in 
5nM treated, uninduced cells were undifferentiable from untreated, uninduced levels. 
Spontaneous expression of luciferase under mTOR inhibition continued to increase in the 
truncated promoters, but only following E2-2 deletions. 
 
4.3 Shifts in YY1 Localization Due to mTOR Inhibition and Viral Induction in 
AGS-BX1 and Raji Cells 
 Since YY1 localization may be impacted through the phosphorylation of its 
serine/threonine residues, it was hypothesized that inhibition of mTOR would alter 
localization differently in each cell type. The results support this hypothesis as YY1 was 
43 
 
observed localizing to the nucleus under mTOR inhibition in Raji B-lymphocytes in both 
treated, uninduced and treated, induced cells. Interestingly, YY1 nuclear localization was 
also observed in the untreated, induced Raji cells. This may be due to YY1’s assumed 
role in B-lymphocytes as a promoter of latency, with EBV entering latency at the time 
cells were harvested (24 hours post induction). The treatment of rapamycin at 1nM and 
5nM in induced Raji cells seemed to compound these effects, with YY1 nuclear 
localization increasing threefold in 5nM treated, induced cells. Treatment of induced Raji 
cells with 10nM rapamycin, however, resulted in the same localization value as reported 
in the 5nM, uninduced samples. It is possible that treatment with 10nM rapamycin 
suppressed EBV lytic replication sufficiently as to no longer trigger latency-associated 
YY1 localization. 
 In contrast, mTOR inhibition was not observed to substantially alter YY1 
localization within AGS-BX1 cells. While there was a slight shift into the cytosol, this 
shift was independent of rapamycin treated or induction state. This suggests that, while 
YY1 localization may alter slightly under general stress-induced pathways within 
epithelial cells, it is not the principle cause behind rapamycin-associated enhancement of 
viral activity. Instead, the potential change in phosphorylation state of YY1 in epithelial 
cells may lead to changes in activation efficiency independent of localization. This may 
be due to changes in DNA binding, as well as protein interactions. 
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4.4 RNAi Mediated Knockdown of YY1 in AGS-BX1 and Raji Cells Alters 
Expression of BZLF1 
 Knockdown of YY1 in AGS-BX1 cells decreased the activating effects of mTOR 
inhibition on BZLF1 expression in treated, induced cells. This effect was most 
pronounced at 1nM and 10nM rapamycin, in which BZLF1 levels were indistinguishable 
from the untreated, induced samples. Additionally, when protein levels were standardized 
to the untreated, uninduced control, it was observed that BZLF1 levels were elevated in 
the 0nM, induced sample compared to the scrambled control. This is similar to the 
expression pattern seen in the ZP(-309) luciferase assay, in which luciferase activity 
decreased relative to the untreated, induced sample but increased relative to the untreated, 
uninduced sample. Furthermore, YY1 knockdown AGS-BX1 cells demonstrated a loss in 
rapamycin-associated repression of spontaneous EBV activation. These results support 
the earlier findings of this projects that YY1 in epithelial cells plays an activating role of 
BZLF1 under mTOR inhibition (Figure 4.1). According to this hypothesis, mTOR 
inhibition leads to a decrease in YY1 phosphorylation, which prolongs the activating 
effect of YY1 on BZLF1 expression. This leads to a more robust expression of BZLF1 
and subsequent increase in activation of downstream lytic proteins. It is interesting that, 
while the luciferase data suggested E2-2 as an enhancer of overall lytic enhancement of 
BZLF1, the knockdown of YY1 produced similar results. This suggests that YY1 
interactions with E2-2 may play a crucial role in modulating over expression levels of the 
immediate-early gene BZLF1. 
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 Knockdown in Raji B-lymphocytes resulted in the significant increase in BZLF1 
expression under 1nM rapamycin treatment, and general increase with 5nM rapamycin 
treatment. This is supportive of the hypothesis that YY1 plays a repressive role to BZLF1 
in Raji cells and, under inhibition of mTOR mediated phosphorylation, localizes to the 
nucleus (Figure 4.2). By decreasing YY1 levels through RNAi, less YY1 is localized to 
the nucleus and BZLF1 is transcribed at a rate similar to the untreated samples. While no 
change was seen in BZLF1 expression in the knockdown cells at 10nM treatment and a 
negative trend between BZLF1 expression and rapamycin concentration remained, this 
may be due to an insufficient level of YY1 knockdown to overcome higher rapamycin 
treatment. Expression changes between the experimental conditions and an untreated, 
uninduced standard were unable to be performed do to the undetectable levels of BZLF1 
within the untreated, uninduced samples. It is hypothesized, however, that these overall 
levels would be increased, as YY1 is only known to be a repressor of lytic replication in 
B-lymphocytes. 
 
4.5 Conclusion 
 In this project, it has been suggested that the cell-specific effects of mTOR 
inhibition are mediated through the activities of the transcription factor YY1. In epithelial 
cells, YY1 binding to the BZLF1 promoter under mTOR inhibition activates expression. 
This activating role on the BZLF1 promoter was seen in both the luciferase assay and the 
YY1 knockdown assay. The activating effect may be due to epithelial-specific post-
translational modification of YY1 such as phosphorylation, alternate protein interactions, 
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or a combination thereof. Given previous studies22 which observed the activating effects 
of E2-2 on the BZLF1 promoter in epithelial cells, YY1 may interact with or affect the 
binding of E2-2. This is further supported by the close proximity of many of the YY1 and 
E2-2 domains on the upstream BZLF1 promoter. 
 
 
 
Figure 4.1. Hypothetical Model of BZLF1 Enhancement through mTOR Inhibition 
in Epithelial Cells. While mTOR activity did not alter YY1 localization to the nucleus, 
YY1 appears to increase BZLF1 activation under mTOR inhibition. Rapamycin 
inhibition of mTOR increases YY1’s activating role, thereby leading to an increase in 
viral replication. 
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Figure 4.2. Hypothetical Model of BZLF1 Repression through mTOR Inhibition in 
B-lymphocytes. Activated mTOR phosphorylates YY1, leading to the cytosolic 
localization of YY1. Under mTOR inhibition, YY1 accumulates in the nucleus, acting a 
repressor to BZLF1 expression. Without BZLF1 expression, the whole lytic replication 
cascade is dramatically reduced. 
 
 
 Conversely, YY1 maintains a repressive role of BZLF1 activation in B-
lymphocytes. Rapamycin sensitivity appears to be mediated by increased nuclear 
localization of YY1 under mTOR inhibition, suggesting that mTOR may play a role in 
YY1 localization through its kinase activity. Alternatively, a compensatory pathway may 
alter YY1 localization through any number of other post-translational modifications. This 
inhibition of transcription of the BZLF1 gene leads to a dramatic decrease in protein 
levels and, therefore, a reduced lytic cascade. 
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 This research reveals a potentially novel mechanism by which YY1 regulates the 
expression of a viral gene. While YY1 has largely been attributed as a repressor of 
multiple viral promoters, is appears to play an activating role in the BZLF1 expression of 
epithelial cells. Here YY1 is predictably repressive of YY1 in B-lymphocytes, but 
unpredictably activating of BZLF1 expression in epithelial cells. Additionally, this 
research suggests that the regulation of YY1 activity between epithelial cells and B-
lymphocytes may not only be responsible for this cell-specific behavior of EBV, but that 
this regulation is itself cell-specific. This knowledge may have transformative impacts on 
the potential use of rapamycin as a chemotherapeutic drug, as well as elucidate the 
hidden interactions between herpesviruses and their host cells.
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